Results 241 to 250 of about 94,246 (299)

Exploring the Systemic Immune-Inflammation Index as a novel biomarker for nonalcoholic fatty liver disease: a systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Mirchandani M, Jeanty H, Sahu S, Nejati H, Adla Jala SR, Mahapatro A, Jain SM, Nasrollahizadeh A, Arezoo G, Hashemi SM, Amini-Salehi E.   +10 more
europepmc   +1 more source

Exploration of Multiple Non‐Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 396-404, February 2026.
This study investigated multiple non‐invasive tests (NIT) in a phase 2b study of patients with MASH and fibrosis treated with semaglutide. Findings revealed that semaglutide significantly improved NIT scores versus placebo from as early as 28 weeks. The results support the use of NITs to assess a treatment response to semaglutide.
Louise Maymann Nitze, Vlad Ratziu, Arun J. Sanyal, Vincent Wai‐Sun Wong, Clare Balendran, Jan Fleckner, Mette Skalshøi Kjær, Niels Krarup, Quentin M. Anstee   +8 more
wiley   +1 more source

<i>Schisandra chinensis</i> alleviates Hypertriglyceridemia in nonalcoholic fatty liver disease by modulating the gut microbiota and hepatic lipid metabolism: identification of its active fractions. [PDF]

Front Pharmacol
Li Q, Feng M, Luo Q, Ye CY, Luo YK, Xu LY.   +5 more
europepmc   +1 more source

Unveiling the Crucial Nexus: Mitochondrial Quality Control as a Central Driver in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis

Cell Proliferation, Volume 59, Issue 2, February 2026.
Mitochondrial quality control (MQC) impairment plays a central role in driving the pathogenesis of metabolism‐associated steatotic liver disease (MASLD). Specifically, this is manifested as reduced mitophagy; increased mitochondrial fission and decreased fusion; and impaired mitochondrial biogenesis.
Wenkai Fu, Junqi Wang, Nan Lu, Zhijiang Guo, Sang‐Bing Ong, Yong Gao, Hao Zhou, Xing Chang, Miao Meng   +8 more
wiley   +1 more source

Ninety‐Day Readmission and Morbidity Following Liver Transplantation for MASLD

Clinical Transplantation, Volume 40, Issue 2, February 2026.
ABSTRACT Introduction The incidence of short‐term (90‐day) hospital readmission and morbidity following liver transplantation (LT) for metabolic dysfunction‐associated steatotic liver disease (MASLD) is poorly characterized, and no study to date has distinguished these short‐term outcomes between MASLD and non‐MASLD LT recipients. The primary objective
Zachary Leslie, Thomas Leventhal, Sean Nguyen, David Leishman, Cheyenna Espinoza, Eric Wise, Sayeed Ikramuddin, Raja Kandaswamy, Abraham J. Matar   +8 more
wiley   +1 more source

Metabolic traits as mediators between excess salt intake and the risk of nonalcoholic fatty liver disease. [PDF]

Medicine (Baltimore)
Li R, Hu K, Cui L, Sun S, Xie Y.
europepmc   +1 more source

Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 214-226, February 2026.
Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki   +4 more
wiley   +1 more source

Corrigendum: Characterization of the hepatic flora and metabolome in nonalcoholic fatty liver disease. [PDF]

Front Microbiol
Jiang H, Wang H, Guo Y, Zhu Y, Dai H, Liang C, Gao J.   +6 more
europepmc   +1 more source

Comorbidities in People With Intellectual Disability With and Without Schizophrenia and Schizophrenia Without Intellectual Disability: A Swedish Register Study (IDcare)

Journal of Intellectual Disability Research, Volume 70, Issue 2, Page 206-217, February 2026.
ABSTRACT Background Intellectual disability (ID) and schizophrenia are known to separately carry a high risk of comorbidity of mental health and physical conditions. However, the prevalence and risk of comorbidities among people diagnosed with concurrent ID and schizophrenia have to date not been studied.
Trine Lise Bakken, Anna Axmon, Magnus Sandberg   +2 more
wiley   +1 more source